Lyell Immunopharma Goes All-In on AWS as its Cloud Provider
19 May 2020 - 11:00PM
Business Wire
Cellular therapy company seeks to accelerate
research of cell-based immunotherapies for cancer and other
diseases by relying upon AWS’s unmatched portfolio of cloud
services
Today, Amazon Web Services, Inc. (AWS), an Amazon.com company
(NASDAQ: AMZN), announced that Lyell Immunopharma is going all-in
on AWS—running its cloud infrastructure on AWS—and has selected AWS
as its standard for machine learning (ML) workloads. Lyell
leverages AWS’s highly performant and scalable infrastructure to
run its secure data and analytics platform as well as support its
high-performance computing workloads to accelerate the research of
new cell therapies as it searches for cures for cancer.
AWS’s breadth and depth of services is helping Lyell to uncover
insights in scientific data on how the immune system can fight
cancer, as well as speed up its research. One of Lyell's approaches
to developing immunotherapies is using high performance computing
(HPC) clusters to help scientists design new protein structures to
engineer immune cells that are more capable of fighting cancer.
Using AWS’s secure and elastic compute capacity, Lyell is able to
design and test potential new cell therapy constructs at a faster
rate, going from conducting a single simulation in four weeks to
completing 30 simulations in 10 hours. By building a data lake on
Amazon Simple Storage Service (Amazon S3), and leveraging AWS
analytics services such as Amazon Athena and Amazon EMR, Lyell can
now analyze petabytes of research, clinical, and manufacturing data
to gain insights into immune cell functionality faster than ever
before. Lyell is also using Amazon SageMaker to enable scientists
to build, train, and deploy ML models. These models enable
automated image analysis and optimization of protein structures,
which will facilitate Lyell’s mission to cure cancer.
“We chose AWS because its unmatched portfolio of cloud services
provides us with the environment and resources we need to research,
design, and develop immunotherapies, all of which wouldn’t be
possible at the speed and scale we are looking for, without the
elasticity of the cloud,” said Rick Klausner, M.D., Founder and
Chief Executive Officer. “Our prominent team of scientists are now
equipped to gain better research insights faster. AWS gives us the
ability to scale quickly while meeting security and compliance
requirements, which is essential to accomplishing our goal of
creating a new generation of cell-based therapies to cure
cancer.”
“By adopting cloud-first strategies on AWS and leveraging the
most comprehensive set of cloud services in the industry,
innovators like Lyell are able to build and scale their businesses,
disrupting longstanding business models and inventing new ones,”
said Mike Clayville, Vice President, Worldwide Commercial Sales at
AWS. “Lyell runs on AWS because we enable them to build and test
applications quickly, and gain insights into vast amounts of data,
with the goal of enabling them to bring new therapies to market,
which is so important in a world where we are all touched by
someone who has been afflicted with cancer. We’re excited to
continue our work with Lyell as they innovate to deliver promising
new therapies to treat cancer.”
About Amazon Web Services
For 14 years, Amazon Web Services has been the world’s most
comprehensive and broadly adopted cloud platform. AWS offers over
175 fully featured services for compute, storage, databases,
networking, analytics, robotics, machine learning and artificial
intelligence (AI), Internet of Things (IoT), mobile, security,
hybrid, virtual and augmented reality (VR and AR), media, and
application development, deployment, and management from 76
Availability Zones (AZs) within 24 geographic regions, with
announced plans for nine more Availability Zones and three more AWS
Regions in Indonesia, Japan, and Spain. Millions of
customers—including the fastest-growing startups, largest
enterprises, and leading government agencies—trust AWS to power
their infrastructure, become more agile, and lower costs. To learn
more about AWS, visit aws.amazon.com.
About Amazon
Amazon is guided by four principles: customer obsession rather
than competitor focus, passion for invention, commitment to
operational excellence, and long-term thinking. Customer reviews,
1-Click shopping, personalized recommendations, Prime, Fulfillment
by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets,
Fire TV, Amazon Echo, and Alexa are some of the products and
services pioneered by Amazon. For more information, visit
www.amazon.com/about and follow @AmazonNews.
About Lyell Immunopharma
Lyell is addressing the unsolved problem of creating reliable,
curative adoptive cell therapy for solid tumors. Lyell brings
together an unrivalled scientific team with a collection of novel
technologies aimed at tackling the three barriers to this unsolved
challenge:
- Redefining the starting cell preparations for cell-based
immunotherapy by taking a cell-and developmental-biology approach,
following the decades-long work of two Lyell scientific leaders,
Stan Riddell and Nick Restifo
- Modulating T cells to maintain their functionality within the
solid tumor microenvironment, with special attention to preventing,
controlling and reversing the differentiation of T cells into
dysfunctional states within solid tumors
- Controlling the specificity and safety of solid tumor-directed
T cells armed with TCRs, CARs or other targeting modalities using
state-of-the-art protein engineering
These three goals define the scientific triad of approaches that
we believe will overcome the functional barriers to reliable and
successful curative therapies. While we are focused on autologous T
cells, we believe that we are developing technologies that will be
useful to cell therapies broadly, potentially including allogeneic
approaches. For further information please visit www.lyell.com or
follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200519005109/en/
Amazon.com, Inc. Media Hotline Amazon-pr@amazon.com
www.amazon.com/pr
Amazon.com (NASDAQ:AMZN)
Historical Stock Chart
From Apr 2024 to May 2024
Amazon.com (NASDAQ:AMZN)
Historical Stock Chart
From May 2023 to May 2024